Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein

European Journal of Cancer

Volumn 29, Issue 3, 1993, Pages 408-415

  Barrand, M A ^a   Rhodes, T ^a   Center, M S ^b   Twentyman, P R ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; MEMBRANE PROTEIN; VALSPODAR; VERAPAMIL; VINCRISTINE;

ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CYCLOSPORINE; CYCLOSPORINS; DAUNORUBICIN; HUMAN; LUNG NEOPLASMS; MEMBRANE PROTEINS; MOLECULAR WEIGHT; NEOPLASM PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED; VERAPAMIL; VINCRISTINE;

EID: 0027473114     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(93)90397-X     Document Type: Article

References (31)

1. P-glycoprotein: multidrug resistance and a superfamily of membrane-associated transport proteins
2. Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein
3. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line
4. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to vinca alkaloids independent of P-glycoprotein
5. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells
6. Derivation and preliminary characterization of adriamycin resistant lines of human lung cancer cells
7. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression
8. Non-P-glycoprotein-mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line
9. Differences between monoclonal antibodies in immunohistochemical detection of P-glycoprotein in human and mouse multidrug resistant cell lines
10. Pharmacology of drugs that alter multidrug resistance in cancer
11. Cyclosporins as drug resistance modifiers
12. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines
13. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein
14. Combined in vitro modulation of adriamycin resistance
15. SDZ-PSC-833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier
16. Effects of cyclosporin A and verapamil on cellular pharmacokinetics and chemosensitivity in an MDR cell line which does not express P-glycoprotein
17. Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein
18. Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon growth of parent and multidrug resistant human lung cancer cells in vitro
19. Confocal microscopy of anthracycline subcellular localization in classic and atypical multidrug resistance (MDR)
20. Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies
21. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA
22. +-adenosine triphosphatase activity in multidrug resistance in HL60 cells
23. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line
24. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin
25. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells
26. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells
27. The multidrug transporter: rapid modulation of efflux activity monitored in single cells by the morphologic effects of vinblastine and daunomycin
28. Verapamil and cyclosporin A modulate doxorubicin toxicity by distinct mechanisms
29. Cyclosporin A and verapamil have different effects on energy metabolism in multi-drug resistant tumour cells
30. Lectin-binding sites as markers of Golgi subcompartments: proximal-to-distal maturation of oligosaccharides
31. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy